Sign in to confirm you’re not a bot
This helps protect our community. Learn more

Brett Favre Shares Why He Supports Odyssey Health’s New Concussion Treatment

RedChip Companies
25.5K subscribers
5.1K views 2 years ago
Pro Football Hall of Fame QB Brett Favre discusses why he supports an innovative new concussion treatment in development by Odyssey Health (OTC: ODYY) in this exclusive RedChip interview. Odyssey’s novel pharmaceutical compound, PRV-002, is intended for the treatment of concussion. PRV-002 is a new chemical entity administered nasally with proven in-vivo efficacy and safety in concussion models. Pre-clinical results show significantly improved sensory motor function and significantly improved memory scores. The drug is currently in a Phase 1 human trial. Visit ODYYinfo.com to learn more. ...more
...more
Brett Favre Shares Why He Supports Odyssey Health’s New Concussion Treatment
N/ALikes
5,114Views
2022Jul 11
Pro Football Hall of Fame QB Brett Favre discusses why he supports an innovative new concussion treatment in development by Odyssey Health (OTC: ODYY) in this exclusive RedChip interview. Odyssey’s novel pharmaceutical compound, PRV-002, is intended for the treatment of concussion. PRV-002 is a new chemical entity administered nasally with proven in-vivo efficacy and safety in concussion models. Pre-clinical results show significantly improved sensory motor function and significantly improved memory scores. The drug is currently in a Phase 1 human trial. Visit ODYYinfo.com to learn more.

Follow along using the transcript.

RedChip Companies

25.5K subscribers